We want to make a real difference to the people we help to create greater value for our company and all our stakeholders.Find out more>
Our proven business model helps us to deliver on our mission of enabling people with life-altering conditions to lead better lives, through leading the way in our chosen specialist areas.
We focus on small-molecule medications within the therapeutic areas of Behavioral Health, where we maintain a leadership position, and Gastro Intestinal disease, among others.
This business is solely focused on researching, developing and marketing novel products and services that profoundly enhance the quality of life of patients suffering from rare genetic diseases.
A leader in providing regenerative medicine solutions for people with life-altering conditions. We aspire to harness the power of regenerative medicine to address society’s unmet medical needs, and are focused on developing and delivering solutions that support the body’s natural healing process.
The world is changing, providing an opportunity for new ideas, approaches and solutions. By changing in the right way we maintain and live up to our role as an industry leader but more importantly offer patients medicines and hope of a
This year saw us continue to deliver on our growth commitments and further advance our pipeline. We articulated a 2020 vision and built on our unique culture of aspiring to be as brave as the people we help.
Angus Russell - Chief Executive Officer
At Shire we have always embraced change as an opportunity to become even better. Looking ahead, we are well prepared to enjoy the next chapter of growth in our ongoing story.
Matthew Emmens - Chairman
We are focused on delivering demonstrable value.
Shire measures its performance using both financial and non financial Key Performance Indicators (“KPIs”).
Revenue growth from net product sales ($BN)
Year on year growth in 2012
We know that putting patients at the heart of everything we do in order to enable them to lead better lives creates big responsibilities for us.
The Group has adopted a risk management strategy designed to identify, assess and manage the significant risks that it faces.
A sound governance structure engenders a successful company.
The Board is committed to high standards of corporate governance which is the foundation of a sustainable and successful company.
Closely linked to governance is culture. The Board works with management to set the values of the Company and to create a culture which promotes integrity, responsibility and putting the patient at the heart of what we do.
The Board’s core activities in 2012 included the review of the Company’s long term strategy, the monitoring of performance, consideration of the risk identification and management system, the review of material risks, and board and management succession.
Matthew Emmens -